BeiGene Ltd. (NASDAQ: ONC) saw its stock price plummet 5.25% in pre-market trading on Wednesday, despite reporting strong first-quarter 2025 financial results and maintaining its full-year guidance. The global oncology company, which is set to change its name to BeOne Medicines Ltd., announced its Q1 performance and business updates after market close on Tuesday.

The company reported a significant 49% increase in total revenues to $1.1 billion for the first quarter, primarily driven by the strong performance of its flagship product, BRUKINSA (zanubrutinib). Global sales of BRUKINSA surged 62% to $792 million compared to the same period last year. Notably, BeiGene achieved GAAP profitability for the first time, reporting a net income of $1.27 million, or $0.01 per American Depositary Share (ADS), compared to a net loss of $251.15 million, or $2.41 per ADS, in Q1 2024.

Despite these positive results, investors seemed to focus on other aspects of the report. The company maintained its full-year 2025 revenue guidance of $4.9 billion to $5.3 billion, which aligns with the current consensus estimate of $5.09 billion. This unchanged outlook, combined with potential concerns about the sustainability of growth rates and increasing competition in the oncology market, may have contributed to the stock's pre-market decline. Additionally, some investors might be taking profits after the stock's recent strong performance.